Northwest Biotherapeutics (NWBO) Income Statement

Click line-items for a historical chart and %

Research material sales
Contract research and development from related parties
Research grants and other
Total revenues	159K
Cost of research material sales
Research and development	21.09M
General and administration	4.58M
Depreciation and amortization
Loss on facility sublease
Asset impairment loss and other (gain) loss
Total operating costs and expenses	25.68M
Loss from operations	-25.52M
Other income (expense):
Valuation of reclassified equity contracts
Loan conversion inducement	-1.46M
Derivative valuation gain (loss)
Gain on sale of intellectual property and property and equipment
Interest expense	-691K
Interest income and other
Net loss	-29.23M
Issuance of common stock in connection with elimination of Series A and Series A-1 preferred stock preferences
Warrants issued on Series A and Series A-1 preferred stock dividends
Accretion of Series A preferred stock mandatory redemption obligation
Series A preferred stock redemption fee
Beneficial conversion feature of Series D preferred stock
Net loss applicable to common stockholders	-32.23M
Net loss per share applicable to common stockholders - basic and diluted ( in dollars per share)
Weighted average shares used in computing basic and diluted net loss per share (in shares)
Other income (expense):
Modification of preferred stock warrants
Preferred stock dividends
Other income (expense):
Modification of preferred stock warrants
Preferred stock dividends

Entities mentioned with NWBO

View All Entities